AI Automated Translation.

Font Size

Share

SG Medical, Q3 operating profit up 204% year-on-year… Subsidiary D-Power turns profitable

SG Medical, Q3 operating profit up 204% year-on-year… Subsidiary D-Power turns profitable

Q3 revenue of 18.6 billion won and operating profit of 3 billion won… Up 64% and 204%, respectively, from the same period last year
Cumulative revenue of 46.9 billion won, achieving 99% of last year’s annual performance… Pushing for expansion into new businesses

Exterior view of SG Medical headquarters /Photo=SG Medical
Exterior view of SG Medical headquarters /Photo=SG Medical

Driven by growth in its core medical device business and improved performance at subsidiary D-Power, SG Medical more than tripled its operating profit in the third quarter of this year compared to the same period last year. Revenue also surged by over 60% during the same period, raising the possibility of setting a new annual revenue record.

SG Medical announced on the 16th that it recorded consolidated revenue of 18.6 billion won and operating profit of 3 billion won in the third quarter of this year. These figures represent increases of 64% and 204%, respectively, compared to the same period last year. The operating margin was 16%, up 7 percentage points from 9% in the same period last year.

Cumulative consolidated revenue for January through September this year was 46.9 billion won, a 31% increase from the same period last year. Operating profit for the same period was 3.6 billion won, an increase of approximately 3%. The cumulative revenue is just 300 million won short of the annual maximum revenue of 47.2 billion won recorded last year.

The core medical device business continued its growth trend. SG Medical’s cumulative standalone revenue for the third quarter was 26.1 billion won, up 26% from the same period last year. This was due to expanded supply of implant prosthetics-related products centered on the digital dentistry business, as well as increased revenue in the spinal and orthopedic medical device sectors. Standalone overseas revenue rose by 23% to 12.1 billion won.

Subsidiary D-Power contributed significantly to the improvement in consolidated performance. D-Power’s third-quarter revenue was 6.8 billion won, more than triple the 2.2 billion won recorded in the same period last year. Operating profit turned from a loss in the same period last year to a surplus of 1.2 billion won.

D-Power’s cumulative third-quarter revenue was 14.1 billion won and operating profit was 1.9 billion won, surpassing both last year’s annual figures of 12.2 billion won in revenue and 900 million won in operating profit. The cumulative operating profit also exceeded the approximately 1.8 billion won recorded in 2022, which had been the highest annual figure in the past five years.

D-Power is a company that supplies electricity meters and communication modules for remote meter reading. Performance improved as orders from Korea Electric Power Corporation’s next-generation electricity meter project, “Amigo (AMIGO),” were reflected in revenue.

Profitability improvements were also seen at dental-related subsidiaries. Implant prosthesis specialist All-Vertment saw its operating profit increase year-on-year in the third quarter of this year.

SG Medical plans to push for expanded revenue contribution from new businesses starting in the fourth quarter. The company aims to cultivate new revenue sources, including an extracellular matrix (ECM)-based skin booster business, a contract development and manufacturing (CDMO) supply agreement with Kolon Pharmaceutical for acellular dermal matrix (ADM), and ECM business cooperation with Live Science.

Yoo Hyeon-seung, CEO of SG Medical, stated, “This third-quarter performance is the result of solid growth in our core business and improved performance at key subsidiaries.” He added, “We expect revenue contribution from new businesses such as ECM skin boosters to fully materialize starting in the fourth quarter, and plan to accelerate the expansion of new revenue based on the ADM CDMO supply agreement with Kolon Pharmaceutical and the ECM business cooperation with Live Science.”

He further added, “By adding the results of new businesses to our existing core operations, we will continue to drive external growth and profitability improvements while raising corporate valuation.”

"This article was translated using AI and may differ slightly from the original."